Mucosal surfaces, such as the lining of the mouth and anus, are a portal of entry for HIV infection, particularly since they lead to the intestine where the conditions for the virus to replicate are optimal. Thus, developing a vaccine that would prevent HIV entry through mucosal surfaces is paramount to fighting the AIDS epidemic.
A team of researchers lead by Jay Berzofsky at the US National Cancer Institute compared the protective ability of a vaccine given subcutaneously (s.c.) and intrarectally to macaque monkeys (Nature Medicine). The vaccine was a combination of peptides based on the HIV virus known to stimulate antibodies and other cytotoxic cells. The scientists found that when they administered the vaccine (plus an adjuvant to stimulate a response) at the mucosal surface of the rectum it was more effective at preventing infection with simian/human immunodeficiency virus (SHIV) than when the same vaccine was administered s.c.
Dr Jay A. Berzofsky
Molecular Immunogenetics and Vaccine Research Section
National Cancer Institute
Telephone: +1 301 496 6874
Fax: +1 301 496 9956
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking